UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009547
Receipt number R000011185
Scientific Title Prospectivestudy on the treatment effect of pancrelipase on chronic pancreatitis patient's alubumin concentration
Date of disclosure of the study information 2013/01/01
Last modified on 2012/12/14 11:04:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospectivestudy on the treatment effect of pancrelipase on chronic pancreatitis patient's alubumin concentration

Acronym

Examination of effect to albumin with pancrelipase in chronic pancreatitis

Scientific Title

Prospectivestudy on the treatment effect of pancrelipase on chronic pancreatitis patient's alubumin concentration

Scientific Title:Acronym

Examination of effect to albumin with pancrelipase in chronic pancreatitis

Region

Japan


Condition

Condition

Chronic pancreatitis

Classification by specialty

Hepato-biliary-pancreatic medicine Hepato-biliary-pancreatic surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the treatment effect of pancrelipase on the chronic pancreatitis

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Improvement of albumin

Key secondary outcomes

1)Change of amylase and lipase
2)Improvement of nutrition
3)Improvement of VAS score
4)Improvement of dyspepsia
5)Improvement of stool consistency and count


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

600mg of Pancrelipase (granules or capsels) to be taken three times a day (1800mg /day) after meals for 4 weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Chronic pancreatitis patients
1)Patient who has intention according to plan
2)Patient who is sign in document
3)Patient suffering from dyspepsia
4)Patient whose BT-PABA test results are 70% or less (Suspected CP or early-stage CP)

Key exclusion criteria

1)Alegyin procion protein or digestive enzym
2)Case with possibility of pregnancy,during nursing
3)Participates in other examinations.
4)Sever infection
5)In addition, the case judged to be inappropriate for the examination to carry out this study safely

Target sample size

83


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazuo Inui

Organization

Department of Internal Medicine Second Teaching Hospital Fujita Health University School of Medicine

Division name

Gastroenterology

Zip code


Address

3-6-10,Otobashi,Nakagawa-ku,Nagoya

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Tomoji Yamamoto

Organization

Department of Internal Medicine Second Teaching Hospital Fujita Health University School of Medicine

Division name

Gastroenterology

Zip code


Address

3-6-10,Otobashi,Nakagawa-ku,Nagoya

TEL


Homepage URL


Email



Sponsor or person

Institute

Department of Internal Medicine Second Teaching Hospital Fujita Health University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

藤田保健衛生大学病院(愛知県)
藤田保健衛生大学第二教育病院(愛知県)
名古屋市立大学病院(愛知県)
三重大学医学部附属病院(三重県)
愛知医科大学病院(愛知県)
岐阜大学医学部附属病院(岐阜県)
NTT西日本東海病院(愛知県)
静岡県立総合病院(静岡県)
医療法人光生会病院(愛知県)
岐阜県総合医療センター(岐阜県)
国民健康保険坂下病院(岐阜県)
独法国立病院機構 静岡医療センター(静岡県)
愛知県がんセンター中央病院(愛知県)
名古屋第二赤十字病院(愛知県)
春日井市民病院(愛知県)
朝日大学歯学部附属村上記念病院(岐阜県)
岐阜市民病院 消化器内科(岐阜県)
岐阜県立多治見病院(岐阜県)


Other administrative information

Date of disclosure of the study information

2013 Year 01 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2012 Year 07 Month 12 Day

Date of IRB


Anticipated trial start date

2012 Year 08 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 12 Month 14 Day

Last modified on

2012 Year 12 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011185


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name